Skip to main content
CNXU logo

Conexeu Sciences Inc.

CNXUNASDAQHealthcareBiotechnology

$3.06Today:- (-)

As of Oct 16, 2026 close

Market cap
$106.54M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$3.05$18.79
Volume (live)
-
Avg. volume (3M)
279.08K

Conexeu Sciences (CNXU) Financial Ratios

For fiscal 2025 (fiscal year ended Oct 31, 2025), Conexeu Sciences had return on equity of -105.4% (up from -1586.3%), debt-to-equity of 0.00 (down from 1.12), a current ratio of 22.20 (up from 1.02) and return on assets of -60.0%. A current ratio of 22.20 means current assets exceed current liabilities.

Conexeu Sciences Financial Ratios Analysis

Valuation, profitability, leverage, and liquidity ratios

Scroll to see more
BreakdownFY 2025FY 2024FY 2023
Period endingOct 2025Oct 2024Oct 2023
Valuation Ratios
Enterprise Value Ratios
Profitability & Returns
Return on Equity (ROE)-105.36%-1586.27%-
Return on Assets (ROA)-60.03%--
Return on Capital Employed (ROCE)-53.70%-333.00%101.40%
Leverage & Solvency Ratios
Debt/Equity0.001.12-0.12
Liquidity Ratios
Current Ratio22.201.02-
Quick Ratio20.270.92-
Efficiency Ratios
Yield & Distribution Ratios
Buyback Yield-87.74%-286.25%-

Source: Company financial statements from annual and quarterly filings. Data as of Jul 31, 2026. Data sources and methodology

Frequently Asked Questions About Conexeu Sciences Financial Ratios

What is Conexeu Sciences's return on equity?

Conexeu Sciences's return on equity (ROE) was -105.4% for fiscal 2025 (period ended Oct 31, 2025). It was -1586.3% a year earlier.

What is Conexeu Sciences's debt-to-equity ratio?

Conexeu Sciences's debt-to-equity ratio was 0.00 for fiscal 2025 (period ended Oct 31, 2025). It was 1.12 a year earlier.

What is return on equity (ROE)?

Return on equity is net income divided by shareholders' equity. It measures how much profit a company generates from the capital its shareholders have invested. Full definition